XOMA Ltd. and Les Laboratoires Servier have signed an agreement to jointly develop and commercialize XOMA 052 in multiple indications. XOMA 052, an anti-inflammatory drug candidate, is designed to inhibit cytokine interleukin-1 beta, which is believed to be a primary trigger of pathologic inflammation in multiple diseases. XOMA will receive approximately $35 million upfront and as much as $470 million in milestone payments and royalties. XOMA retains development and commercialization rights ...